Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05238922 · ClinicalTrials.gov registry record · Phase 1

Study of INCB123667 in Subjects With Advanced Solid Tumors

A Phase 1 study of Solid Tumors, sponsored by Incyte Corporation.

Recruiting
Registry status
Phase 1
Development phase
604
Enrollment target
20
Study locations

NCT05238922 is a Phase 1 study of Solid Tumors that is actively recruiting participants, run by Incyte Corporation. The registered enrollment target is 604 participants, above the 280-participant average among 125 other Solid Tumors trials with a reported enrollment target (116% higher). The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05238922, a Phase 1 study of Solid Tumors, is actively recruiting participants, sponsored by Incyte Corporation.

RECRUITING
Registry status
Phase 1
Development phase
604 participants
Enrollment target
20
Study locations

Study Summary

This is an open-label, dose-escalation and dose-expansion study to determine the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy of INCB123667 when administered as monotherapy and in combination with anticancer therapies in participants with selected advanced or metastatic solid tumors. This study will consist of 2 parts. In Part 1, INCB123667 will be administered as monotherapy and in Part 2, INCB123667 will be administered in combination with anticancer therapies of interest. Each part will comprise a dose escalation portion (Parts 1a and 2a, respectively) and a dose-expansion portion (Parts 1b and 2b, respectively).

Conditions Studied

Solid Tumors

Interventions

  • DRUG Bevacizumab
  • DRUG Olaparib
  • DRUG Paclitaxel
  • DRUG Palbociclib
  • DRUG INCB0123667

Study Locations (20)

California

  • City of Hope Medical Center - Duarte
  • City of Hope-Lennar Foundation Cancer Center - Irvine
  • Valkyrie Clinical Trials - Los Angeles

New York

  • Memorial Sloan Kettering Cancer Center - New York
  • New York Presbyterian/Weill Cornell - New York
  • Ny Cancer and Blood Specialists - Shirley

Pennsylvania

  • University of Pennsylvania Abramson Cancer Center - Philadelphia
  • University of Pittsburgh Cancer Institute Cancer Services - Pittsburgh
  • Allegheny Health Network - Pittsburgh

Texas

  • Texas Oncology - Austin
  • Texas Oncology-Fort Worth South Henderson - Fort Worth

Colorado

  • Rocky Mountain Cancer Centers-Sky Ridge - Lone Tree

Connecticut

  • Yale Cancer Center - New Haven

Florida

  • Mount Sinai Medical Center Comprehensive Cancer Center - Miami Beach

Georgia

  • Emory University - Atlanta

Trial Details

FieldValue
Enrollment Target 604 participants
Start Date 2022-07-05
Est. Completion 2027-08-31
Phase Phase 1

Sponsor

Incyte Corporation

239 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05238922

The ClinicalTrials.gov registry entry for NCT05238922 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 604 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 280-participant average among 125 other Solid Tumors trials with a reported enrollment target (116% higher). The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Solid Tumors appearing as the primary indexed condition, and to 5 interventions - of which Bevacizumab is the first listed.

NCT05238922 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, New York, Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT05238922 about?

NCT05238922 is a clinical study titled "Study of INCB123667 in Subjects With Advanced Solid Tumors". This is an open-label, dose-escalation and dose-expansion study to determine the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy of INCB123667 when administered as monotherapy and in combination with anticancer therapies in participants with selected advanced or metastatic solid...

What is the current status of trial NCT05238922?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 604 participants. The study started on 2022-07-05. Estimated completion is 2027-08-31.

What conditions does trial NCT05238922 study?

This clinical trial studies the following conditions: Solid Tumors.

What interventions are being tested in trial NCT05238922?

The interventions under investigation include: Bevacizumab (DRUG), Olaparib (DRUG), Paclitaxel (DRUG), Palbociclib (DRUG), INCB0123667 (DRUG).

Who is sponsoring clinical trial NCT05238922?

This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05238922 being conducted?

This trial has 20 study locations across California, Colorado, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Solid Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Solid Tumors

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.